Pathstone Holdings LLC trimmed its stake in PTC Inc. (NASDAQ:PTC – Free Report) by 4.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).

PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

However, on the same day, Robert W. Baird maintained a Buy rating on PTC Therapeutics (NASDAQ: PTCT). The company has a one-year high of $46.98 and a one-year low of $20.75. Currently, PTC ...

In a report released today, Joseph Thome from TD Cowen maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price ...

PTC Therapeutics ( (PTCT) ) just unveiled an update.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

Thank you for standing by, and welcome to Autodesk third quarter and fiscal year 2025 financial results conference call. At ...